Trials / Completed
CompletedNCT01521455
Therapeutic Equivalence Study of HCP0910 250/50 Mcg to Seretide 250 Diskus in Asthmatic Patients
A Phase I, Randomized, Open, Multi-center, Cross Over Study to Evaluate the Therapeutic Equivalence of Repeated Dose of HCP0910 250/50 μg to SeretideTM 250 DiskusTM in Asthmatic Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to prove that HCP0910 is therapeutically equivalent to Seretide 250 Diskus when repeatedly dosed to Asthmatic patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCP0910 | 250/50, BID for 2 weeks |
| DRUG | Seretide Diskus | 250/50, BID for 2 weeks |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2013-06-01
- Completion
- 2013-07-01
- First posted
- 2012-01-30
- Last updated
- 2013-08-23
Locations
7 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01521455. Inclusion in this directory is not an endorsement.